insights_auto
Why is 2359 down 2.19%?
Dive Deeperchevron_right
2359:HKG
WuXi AppTec Ord Shs H
HK$ 196.20
arrow_downward
-2.19%(-4.40) 1D
10-р сарын 16, 16:08:14 (GMT+8) · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
HK$ 203.80
High
HK$ 209.00
Low
HK$ 185.00
Mkt. cap
544.52Т
Avg. vol.
3.91 сая
Volume
10.16 сая
Dividend
1.22%
Quarterly dividend
HK$ 0.60
Ex-dividend date
2026 оны 9-р сарын 4
P/E ratio
23.98
52-wk high
HK$ 219.20
52-wk low
HK$ 96.70
EPS
HK$ 8.18
No. of employees
36 мян
Open
HK$ 203.80
High
HK$ 209.00
Low
HK$ 185.00
Mkt. cap
544.52Т
Avg. vol.
3.91 сая
Volume
10.16 сая
Dividend
1.22%
Quarterly dividend
HK$ 0.60
Ex-dividend date
2026 оны 9-р сарын 4
P/E ratio
23.98
52-wk high
HK$ 219.20
52-wk low
HK$ 96.70
EPS
HK$ 8.18
No. of employees
36 мян
News stories
From web sources and news partners
ad-hoc-news.de
·
1 өдрийн өмнө
Morgan Stanley keeps target for WuXi AppTec stock at HKD 207.40
ad-hoc-news.de
·
2 өдрийн өмнө
Morgan Stanley backs 800-ton expansion for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35.6 мян
Founded2000 оны 12-р сарын 1
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn